Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) Including Those with the 17p Deletion or TP53 Mutation OR Those Who Are Refractory or Intolerant to B-Cell Receptor Inhibitors

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
AbbVie

Protocol Number
AbbVie m15-550

To Learn More Call
201-510-0910